CAS: 142373-60-2; (S)-2-(Butylsulfonamido)-3-(4-(4-(Piperidin-4-yl)Butoxy)Phenyl)Propanoic Acid Hydrochloride
该化合物是一种合成化合物,主要用作急性冠状综合征管理中的抗塑剂;它作为小板上的甘蓝蛋白IIb/III受体的可逆敌体,从而抑制了板块的集聚并并减少了血栓形成的风险;该化合物通常在临床环境中静脉注射;它以白到白晶线外表为特征,在水中可溶解,便于其注射制剂的使用;单水体形式表明与该化合物的每一种分子都存在一种水分子,可影响其稳定性和溶性;分子重量和具体结构特征有助于其致癌特性,包括吸收,分布,新陈代谢和排泄.与许多药物一样,在治疗应用中,认真考虑剂量和潜在副作用至关重要.
- 英文名称(S)-2-(Butylsulfonamido)-3-(4-(4-(Piperidin-4-yl)Butoxy)Phenyl)Propanoic Acid Hydrochloride
- 中文名称盐酸替罗非班
- IUPAC名称(S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid hydrochloride
- 其它别名L-Tyrosine, N-(Butylsulfonyl)-O-(4-(4-Piperidinyl)Butyl)-, Monohydrochloride; N-(Butylsulfonyl)-O-(4-(4-Piperidinyl)Butyl)-L-Tyrosine Monohydrochloride; 2-(Butylsulfonamido)-3-(4-(4-(Piperidin-4-yl)Butoxy)Phenyl)Propanoic Acid; L-Tyrosine,N-(Butylsulfonyl)-O-[4-(4-Piperidinyl)Butyl]-, Hydrochloride (1:1); -3-(4-(4-(Piperidin-4-yl); Butoxy); N-(Butylsulfonyl)-O-[4-(4-Piperidinyl)Butyl]-L-Tyrosine Hydrochloride
- CAS编号142373-60-2
- MFCD编号:MFCD00868210
- FDA UNII编号:IKE1P4X57J
- 分子式:C22H37ClN2O5S分子量:477.07
- 产品CID: 650004
- 同类组份化合物CAS150915-40-5 (HCl hydrate)144494-65-5 (free base)142373-60-2 (HCl)1332075-40-7 (deuterium labeled)1331911-68-2 (deuterium labeled HCl)
- 产品分类原料药 → 循环系统用药 → 防治心绞痛药
物理性质
- 熔点223-225 °C
- 沸点611.7 °C at 760mmHg
- 闪点323.7 °C
- PSA:122.34
- LogP:5.4887
- 蒸汽压8.09E-16mmHg at 25°C
- 溶解性Methanol (Slightly)
- 外观形态白色固体
- 储存条件室温
- 产品应用该化合物是一种可逆的,非对映的甘烃蛋白色素(GP)IIB/III受体抗争剂,它竞相抑制纤维素与板板块GPG IIB /IIIA受体的结合,从而抑制由ADP,丙基酸,丙二甲酸,苯丙酮类U46619和THOMBIN引起的板盘结;延长出血时间;防止血栓形成.指出,在患有不稳定的腹膜或非热性心血管心肌的病人中预防心脏炎事件,以及预防和治疗与正在接受心血管结的病人相关的心血管热性并发症.
合成工艺路线路线简述
📜替罗非班置于盐酸体系中,化学反应 6.0H,以95.7%的收率获得盐酸替罗非班
参考文献:一种盐酸替罗非班的制备工艺
标题:一种盐酸替罗非班的制备工艺
摘要:本发明属于医药化工领域,通过取代,缩合,还原,成盐等反应制备的盐酸替罗非班,具有较高的收率,很好的质量及非常好的稳定性,提供了一种适合实际的工业化大生产的合成工艺.
海关参考信息
- 2902600000-乙苯
2905121000-正丙醇
2905130000-正丁醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2013030282-A1
优先权日:2011-07-18
标题:Synthesis and characterization of near ir fluorescent magnetic and non-magnetic albumin nanoparticles for biomedical applications
发明人：MARGEL SHLOMO; COHEN SARIT; SALKMON ENAV COREM; PELLACH MICHAL
权利人:UNIV BAR ILAN; MARGEL SHLOMO; COHEN SARIT; SALKMON ENAV COREM; PELLACH MICHAL
摘要:The present invention discloses Near Infrared (NIR) fluorescent albumin nanoparticles having a structure selected from a core structure or a core-shell structure. Also disclosed are a process of preparing these NIR fluorescent albumin nanoparticles, and a method of in vivo detection of pathologies, in particular cancer pathology, by using administering these NIR fluorescent albumin nanoparticles to a patient.
专利号:CN-1740158-A
优先权日:2005-09-26
标题:Synthesis process of Tilofiban hydrochloride intermediate
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Bano S, Ahmed FW, Saeed A, Nawazish A, Haris M, Mansoor A, Jamali AG, Ahmed R, Khan SH, Akram N, Salahuddin Z, Umar M, Abufatima IO. Efficacy and safety of Tirofiban following intravenous thrombolysis: a systematic review and meta- analysis of randomized controlled trials. BMC Neurol. 2026 Apr 17. doi: 10.1186/s12883-026-04892-8. Epub ahead of print. 105(16):e48070. doi: 10.1097/MD.0000000000048070.
4: Lu X, Cao L, Zeng L, Zhang L. Tirofiban combined with aspirin for branch atheromatous disease: a propensity score-matched study. Front Neurol. 2026 Apr 1;17:1802990. doi: 10.3389/fneur.2026.1802990.
5: A A, P A, Subramani S, V R. Comment on "Leukoaraiosis in patients with tirofiban before endovascular thrombectomy: A post hoc analysis of a multicentre randomized clinical trial". J Formos Med Assoc. 2026 Apr
合成参考文献
参考文献:10.1007/s11239-010-0457-5
摘要:Campo G, Fileti L, Valgimigli M, Tebaldi M, Cangiano E, Cavazza C, Marchesini J, Ferrari R. Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis. 2010 Feb 16;30(3):319–31. doi: 10.1007/s11239-010-0457-5.
参考文献:10.1007/s11239-010-0454-8
摘要:Lopes RD, Garcia D, Becker RC, Granger CB, Newby LK, Alexander JH, Jolicoeur EM, Handler A, Pieper KS, Carvalho AC, Guimaraes HP, Chamone DAF, Baruzzi AC, Machado FS, Timerman A, Lopes AC. Highlights from the II international symposium of thrombosis and anticoagulation (ISTA), October 22–23, 2009, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis. 2010 Feb 16;29(4):395–408. doi: 10.1007/s11239-010-0454-8.
参考文献:10.1007/s11883-011-0190-3
摘要:Mangalmurti SS, Davidson MH. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct;13(5):373–80. doi: 10.1007/s11883-011-0190-3.
📝 需求与反馈
尽可能描述清楚需求与问题信息
